Early Cancer Detection
Proven ability to detect all stages of canine lymphosarcoma and hemangiosarcoma.
High Detection Rate
Detects 76% of systemic canine cancers at 97% specificity.
Small Sample Size
Only 1 mL of EDTA-plasma needed for all canine breeds and sizes.
Accessible and Affordable
Now cancer screening is easily available at an affordable cost for you and your clients.
Measures levels of nucleosomes circulating in the patient’s blood.
Peer Reviewed Evidence
Methodology backed by studies on canine lymphoma, canine hemangiosarcoma, and other common canine cancers.
Introducing Heska Nu.Q® Canine Cancer Screen & Monitor
Heska is proud to offer a ground-breaking test for dogs that allows veterinarians to screen and monitor for the most common forms of cancer. Detect cancer before it reaches advanced stages.
The Nu.Q Canine Cancer Screen and Monitor measures nucleosomes to provide clinicians with actionable results.
Effective Cancer Screening
Nucleosome measurement provides clinicians reasonable levels of suspicion for active neoplasia.
Early Detection, Earlier Treatment
Early detection leads to more comprehensive and effective treatment for your patient.
Easy Test Submission
Heska has you covered with sample submission kits, including return shipping labels.
In 40 years of business in this industry I have never worked with a better company and better people than Heska.
Paradise Animal Center
Technical Details & Downloads
Canine Cancer Screening in Your Practice
Approximately 6 million dogs are diagnosed with cancer in the United States each year. Early detection can mean better treatment and outcomes for your patients. In partnership with Volition Veterinary, Heska is proud to offer the Nu.Q® Canine Cancer Screen and Monitor. Nearly 50% of dogs over 10 will develop cancer. These diagnoses are often unexpected and debilitating for patients and pet parents alike. Cancer screening with the Nu.Q® Canine Cancer Screen and Monitor aids in early detection, leading to more comprehensive and effective treatment.
Cancer screening with Nu.Q® provides the opportunity to detect cancer early. Studies have shown that measuring nucleosomes in blood has the potential to detect multiple stages of common canine cancers, such as lymphoma and hemangiosarcoma.
Intended for screening dogs 7 years and older, or predisposed individuals and breeds, Nu.Q® Canine Cancer Screen and Monitor allows veterinary professionals the chance to catch cancer early and provide a higher level of care.
Heska has two Nu.Q® test options:
Coming soon the the Element i+® Immunodiagnostic Analyzer. Run the Heska Nu.Q® Canine Cancer Screen & Monitor in your clinic… while your patient waits.
How Does it Work?
During cell death, chromatin is fragmented into nucleosomes, which are released into the bloodstream. Cancer is usually characterized by high levels of cellular turnover, in turn leading to higher levels of nucleosomes circulating in blood. The Nu.Q® Canine Cancer Screen and Monitor measures these nucleosomes to provide clinicians with actionable results.
- 77% of Canine Lymphosarcoma Found – detection of all 5 stages
- 82% of Canine Hemangiosarcoma Found – detection of all 3 stages
- Multi-cancer Study Results: Nu.Q Canine Cancer Screen and Monitor detects 76% of Systemic Cancers at 97% Specificity
Heska Support Teams are Here for You
We’re Available When You Need Us
Rest assured that when you need help, have questions, or have difficulties, we have you covered.
- Available 6:00am – 5:00pm MST Daily
- Emergency Support During Off-Hours
- Case Consultations or Product Usage Help